Usefulness of hybrid veno-arterial extracorporeal membrane oxygenation for lung ischemia-reperfusion injury after biventricular assist device implantation.
Biventricular assist device
Fulminant myocarditis
Hybrid veno-arterial extracorporeal membrane oxygenation
Lung ischemia–reperfusion injury
Journal
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
ISSN: 1619-0904
Titre abrégé: J Artif Organs
Pays: Japan
ID NLM: 9815648
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
31
10
2021
accepted:
28
12
2021
pubmed:
23
1
2022
medline:
31
8
2022
entrez:
22
1
2022
Statut:
ppublish
Résumé
We experienced a case of fulminant myocarditis complicated by severe lung ischemia-reperfusion injury after switching from veno-arterial extracorporeal membrane oxygenation to biventricular assist device. We controlled lung blood flow by hybrid veno-arterial extracorporeal membrane oxygenation, which was established by modifying the biventricular assist device circuit without resternotomy, blood delivery to the pulmonary artery and blood removal from the left ventricle in addition to central veno-arterial extracorporeal membrane oxygenation, and accelerated lung recovery. The patient's lung damage and cardiac function were restored, and she completely recovered and was discharged without any complications. Regulation of lung blood flow is important and effective for lung ischemia-reperfusion injury after biventricular assist device implantation.
Identifiants
pubmed: 35064388
doi: 10.1007/s10047-022-01310-x
pii: 10.1007/s10047-022-01310-x
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-269Informations de copyright
© 2022. The Japanese Society for Artificial Organs.
Références
Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis. A Scientific statement from American Heart Association. Circulation. 2020;141:69–92.
doi: 10.1161/CIR.0000000000000745
van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG, American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–68.
doi: 10.1161/CIRCULATIONAHA.117.029532
Saito S, Toda K, Miyagawa S, Yoshioka Y, Hata H, Yoshioka D, Domae K, Tsukamoto Y, Sakata Y, Sawa Y. Diagnosis, medical treatment, and stepwise mechanical circulatory support for fulminant myocarditis. J Artif Organs. 2018;21:172–9.
doi: 10.1007/s10047-017-1011-4
Laubach VE, Sharma AK. Mechanism of lung ischemia-reperfusion injury. Curr Opin Organ Transplant. 2016;21:246–52.
doi: 10.1097/MOT.0000000000000304
Weyker PD, Webb CA, Kiamanesh D, Flynn BC. Lung ischemia reperfusion injury: a bench-to-bedside review. Semin Cardiothorac Vasc Anesth. 2013;17:28–43.
doi: 10.1177/1089253212458329
den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ, Moens AL. Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol. 2010;299:H1283–99.
doi: 10.1152/ajpheart.00251.2010